Rohun U Palekar1, Chandu Vemuri2, Jon N Marsh3, Batool Arif2, Samuel A Wickline4. 1. Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Mo. 2. Department of Surgery, Washington University in St. Louis, St. Louis, Mo. 3. Department of Medicine, Washington University in St. Louis, St. Louis, Mo. 4. Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Mo; Department of Medicine, Washington University in St. Louis, St. Louis, Mo. Electronic address: wicklines@aol.com.
Abstract
OBJECTIVE: Despite significant advances in intravascular stent technology, safe prevention of stent thrombosis over prolonged periods after initial deployment persists as a medical need to decrease device failure. The objective of this project was to assess the potential of perfluorocarbon nanoparticles (NP) conjugated with the direct thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone (PPACK-NP) to inhibit stent thrombosis. METHODS: In a static model of stent thrombosis, 3 × 3-mm pieces of stainless steel coronary stents were cut and adsorbed with thrombin to create a procoagulant surface that would facilitate thrombus development. After treatment with PPACK-NP or control NP, stents were exposed to platelet-poor plasma (PPP) or platelet-rich plasma (PRP) for set time points up to 60 minutes. Measurements of final clot weight in grams were used for assessing the effect of NP treatment on limiting thrombosis. Additionally, groups of stents were exposed to flowing plasma containing various treatments (saline, free PPACK, control NP, and PPACK-NP) and generated thrombi were stained and imaged to investigate the treatment effects of PPACK-NP under flow conditions. RESULTS: The static model of stent thrombosis used in this study indicated a significant reduction in thrombus deposition with PPACK-NP treatment (0.00067 ± 0.00026 g; n = 3) compared with control NP (0.0098 ± 0.0015 g; n = 3; P = .026) in PPP. Exposure to PRP demonstrated similar effects with PPACK-NP treatment (0.00033 ± 0.00012 g; n = 3) vs control NP treatment (0.0045 ± 0.00012 g; n = 3; P = .000017). In additional studies, stents were exposed to both PRP pretreated with vorapaxar and PPACK-NP, which illustrated adjunctive benefit to oral platelet inhibitors for prevention of stent thrombosis. Additionally, an in vitro model of stent thrombosis under flow conditions established that PPACK-NP treatment inhibited thrombus deposition on stents significantly. CONCLUSIONS: This study demonstrates that antithrombin perfluorocarbon NPs exert marked focal antithrombin activity to prevent intravascular stent thrombosis and occlusion.
OBJECTIVE: Despite significant advances in intravascular stent technology, safe prevention of stent thrombosis over prolonged periods after initial deployment persists as a medical need to decrease device failure. The objective of this project was to assess the potential of perfluorocarbon nanoparticles (NP) conjugated with the direct thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone (PPACK-NP) to inhibit stent thrombosis. METHODS: In a static model of stent thrombosis, 3 × 3-mm pieces of stainless steel coronary stents were cut and adsorbed with thrombin to create a procoagulant surface that would facilitate thrombus development. After treatment with PPACK-NP or control NP, stents were exposed to platelet-poor plasma (PPP) or platelet-rich plasma (PRP) for set time points up to 60 minutes. Measurements of final clot weight in grams were used for assessing the effect of NP treatment on limiting thrombosis. Additionally, groups of stents were exposed to flowing plasma containing various treatments (saline, free PPACK, control NP, and PPACK-NP) and generated thrombi were stained and imaged to investigate the treatment effects of PPACK-NP under flow conditions. RESULTS: The static model of stent thrombosis used in this study indicated a significant reduction in thrombus deposition with PPACK-NP treatment (0.00067 ± 0.00026 g; n = 3) compared with control NP (0.0098 ± 0.0015 g; n = 3; P = .026) in PPP. Exposure to PRP demonstrated similar effects with PPACK-NP treatment (0.00033 ± 0.00012 g; n = 3) vs control NP treatment (0.0045 ± 0.00012 g; n = 3; P = .000017). In additional studies, stents were exposed to both PRP pretreated with vorapaxar and PPACK-NP, which illustrated adjunctive benefit to oral platelet inhibitors for prevention of stent thrombosis. Additionally, an in vitro model of stent thrombosis under flow conditions established that PPACK-NP treatment inhibited thrombus deposition on stents significantly. CONCLUSIONS: This study demonstrates that antithrombinperfluorocarbon NPs exert marked focal antithrombin activity to prevent intravascular stent thrombosis and occlusion.
Authors: D E Cutlip; D S Baim; K K Ho; J J Popma; A J Lansky; D J Cohen; J P Carrozza; M S Chauhan; O Rodriguez; R E Kuntz Journal: Circulation Date: 2001-04-17 Impact factor: 29.690
Authors: Peter B Berger; Deepak L Bhatt; Valentin Fuster; P Gabriel Steg; Keith A A Fox; Mingyuan Shao; Danielle M Brennan; Werner Hacke; Gilles Montalescot; Steven R Steinhubl; Eric J Topol Journal: Circulation Date: 2010-06-01 Impact factor: 29.690
Authors: Julian Ilcheff Borissoff; Sylvia Heeneman; Evren Kilinç; Peter Kassák; René Van Oerle; Kristien Winckers; José W P Govers-Riemslag; Karly Hamulyák; Tilman M Hackeng; Mat J A P Daemen; Hugo ten Cate; Henri M H Spronk Journal: Circulation Date: 2010-08-09 Impact factor: 29.690
Authors: Victor M Victor; Milagros Rocha; Eva Solá; Celia Bañuls; Katherine Garcia-Malpartida; Antonio Hernández-Mijares Journal: Curr Pharm Des Date: 2009 Impact factor: 3.116
Authors: Rohun U Palekar; Jacob W Myerson; Paul H Schlesinger; J Evan Sadler; Hua Pan; Samuel A Wickline Journal: Mol Pharm Date: 2013-10-10 Impact factor: 4.939
Authors: Giulia Magnani; Marc P Bonaca; Eugene Braunwald; Anthony J Dalby; Keith A A Fox; Sabina A Murphy; José Carlos Nicolau; Ton Oude Ophuis; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; David A Morrow Journal: J Am Heart Assoc Date: 2015-03-19 Impact factor: 5.501
Authors: R E Kalinin; I A Suchkov; N D Mzhavanadze; N V Korotkova; O N Zhurina; V O Povarov; I Yu Surov; A D Bozhenova; E A Strelnikova Journal: Bull Exp Biol Med Date: 2021-09-20 Impact factor: 0.804
Authors: Linda Labberton; Ellinor Kenne; Andy T Long; Katrin F Nickel; Antonio Di Gennaro; Rachel A Rigg; James S Hernandez; Lynn Butler; Coen Maas; Evi X Stavrou; Thomas Renné Journal: Nat Commun Date: 2016-09-06 Impact factor: 14.919